Company intelligence / Profile preview

Endor Technologies

Barcelona, Catalonia, Spainendortechnologies.com ↗

Ownership: Private
Employees: ~9
Development stage: Phase 2

Overview

Endor Technologies has developed a recombinant protein therapy targeting immune responses against tumors that has reached Phase II clinical trials for pancreatic and colorectal cancer. Its dermatological R&D has produced a gold nanoparticle-hyaluronic acid conjugate with proven efficacy in skin rejuvenation and firming; these cosmetic products are already marketed internationally.[1][2]

Therapeutic areas: OncologyDermatology
Modalities: Recombinant proteins (oncology)Nanoparticle-based delivery systems (dermatology/cosmetics)Gold nanoparticle-conjugated hyaluronic acid (AuHA™)
Industry: Biotech

Drug pipeline

1 asset

Lasergen

Unknown

Partnerships

Collaboration with the Biomedical Cancer Clinical Center of Hospital Clínic de Barcelona for oncology research.

Beyond the preview

Go deeper on Endor Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endor Technologies.